Hypertension-mediated albuminuria is associated with reduced lysosomal activity in the kidney and the heart

American Journal of Nephrology

Volumn 29, Issue 5, 2009, Pages 454-464

  Hilliard, Lucinda M ^a   Russo, Leileata M ^b   Comper, Wayne D ^a  

^a MONASH UNIVERSITY   (Australia)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ig h3 expression; Cardiac fibrosis; Cardiac hypertrophy; Lysosomal activity; Ramipril; Renal albumin degradation pathway

Indexed keywords

ALBUMIN; CATHEPSIN B; CATHEPSIN L; COLLAGEN; HISTAMINE H3 RECEPTOR; RAMIPRIL; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; HEART; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HEART WEIGHT; HYPERTENSION; KIDNEY; KIDNEY HYPERTROPHY; LYSOSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; WISTAR KYOTO RAT;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CATHEPSINS; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; HYPERTENSION; KIDNEY; LYSOSOMES; MALE; MYOCARDIUM; RAMIPRIL; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 56349170391     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000176535     Document Type: Article

References (61)

1. Russo LM, Comper WD, Osicka TM: Mechanism of albuminuria associated with cardiovascular disease and kidney disease. Kidney Int Suppl 2004;92:S67-S68.
2. Russo LM, Osicka TM, Brammar GC, Candido R, Jerums G, Comper WD: Renal processing of albumin in diabetes and hypertension in rats: possible role of TGF-β Am J Nephrol 2003;23:61-70.
3. Russo LM, Brammar GC, Jerums G, Comper WD, Osicka TM: The effect of ramipril on albumin excretion in diabetes and hypertension: the role of increased lysosomal activity and decreased transforming growth factor-β expression. J Hypertens 2003;21:419-428.
4. Russo LM, Osicka TM, Bonnet F, Jerums G, Comper WD: Albuminuria in hypertension is linked to altered lysosomal activity and TGF-β expression. Hypertension 2002;39: 281-286.
5. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β J Clin Invest 1993;92:1366-1372.
6. Riser BL, Cortes P, Heilig C, Grondin J, Lad-son-Wofford S, Patterson D, Narins, RG: Cyclic stretching force selectively up-regulates transforming growth factor-β isoforms in cultured rat mesangial cells. Am J Pathol 1996;148:1915-1923.
7. Hirakata M, Kaname S, Chung UG, Joki N, Hori Y, Noda M, Takuwa Y, Okazaki T, Fujita T, Katoh T, Kurokawa K: Tyrosine ki-nase-dependent expression of TGF-P induced by stretch in mesangial cells. Kidney Int 1997;51:1028-1036.
8. Li Q, Muragaki Y, Hatamura I, Ueno H, Ooshima A: Stretch-induced collagen synthesis in cultured smooth muscle cells from rabbit aortic media and a possible involvement of angiotensin II and transforming growth factor-β J Vasc Res 1998;35:93-103.
9. Rocco M, Chen Y, Goldfarb S, Ziyadeh FN: Elevated glucose stimulates TGF-P gene expression and bioactivity in proximal tubule. Kidney Int 1992;41:107-114.
10. Ziyadeh FN, Sharma K, Ericksen M, Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 1994;93:536-542.
11. 1. Kidney Int 1992;41:1213-1221.
12. Olbricht CJ, Geissinger B: Renal hypertrophy in streptozotocin diabetic rats: role of proteolytic lysosomal enzymes. Kidney Int 1992;41:966-972.
13. Schaefer L, Meier K, Hafner C, Teschner M, Heidland A, Schaefer RM: Protein restriction influences glomerular matrix turnover and tubular hypertrophy by modulation of renal proteinase activities. Miner Electrolyte Metab 1996;22:162-167.
14. Shechter P, Boner G, Rabkin R: Tubular cell protein degradation in early diabetic renal hypertrophy. J Am Soc Nephrol 1994;4: 1582-1587.
15. 1 on cathepsin activity in cultured kidney tubule cells. Am J Physiol 1995;269:F911-F917.
16. Schenk O, Ling H, Sebeková K, Vamvakas S, Heidland A: High glucose media enhance the responsiveness of tubular cells to growth promoters: effect on lysosomal cathepsins and protein degradation. Miner Electrolyte Metab 1998;24:254-260.
17. Burne MJ, Panagiotopoulos, Jerums G, Comper WD: Alterations in renal degradation of albumin in early experimental diabetes: a new factor in the mechanism of albu-minuria. Clin Sci (Lond) 1998;95:67-72.
18. Strong KJ, Osicka TM, Comper WD: Uri-nary-peptide excretion by patients with and volunteers without diabetes. J Lab Clin Med 2005:145:239-246.
19. Hilliard LM, Osicka TM, Clavant S, Robinson PJ, Nikolic-Paterson DJ, Comper WD: Characterization of the urinary albumin degradation pathway in the isolated perfused rat kidney. J Lab Clin Med 2006; 147: 36-44.
20. Osicka TM, Houlihan CA, Chan JG, Jerums G, Comper WD: Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 2000;49:1579-1584.
21. 1 reduces megalin- and cubilin-medi-ated endocytosis of albumin in proximal-tubule- derived opossum kidney cells. J Physiol 2003:552:471-481.
22. 1 in the induction of postglomer-ular albuminuria in diabetic nephropathy: amelioration by soluble TGF-β type II receptor. Diabetes 2007;56:380-388.
23. Baricos WH, Zhou Y, Fuerst RS, Barrett AJ, Shah SV: The role of aspartic and cysteine proteinases in albumin degradation by rat kidney cortical lysosomes. Arch Biochem Biophys 1987;256:687-691.
24. Olbricht CJ: Distribution of cathepsins B and L in the kidney and their role in tubular protein absorption. Eur J Clin Chem Clin Biochem 1992:30:675-681.
25. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, Bauer EP, Klovekorn WP, Schaper J: Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003; 107:984-991.
26. 1 and their receptors in patients with idiopathic hypertrophic cardiomyopathy: a possible mechanism. Circulation 1998;98(suppl 19): II144-II149.
27. 1 in normal heart and in myocardial infarction. Ann NY Acad Sci 1990;593:148-160.
28. 3 in cardiomyocytes during pressure overload-induced hypertrophy. J Mol Cell Cardiol 1997;29:2213-2224.
29. 1. Am J Physiol 2002;283:H1253-H1262.
30. Suzuki H, Schaefer L, Ling H, Schaefer RM, Dammrich J, Teschner M, Heidland A: Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases. Am J Nephrol 1995;15:129-136.
31. Stypmann J, Gläser K, Roth W, Tobin DJ, Petermann I, Matthias R, Mönnig, Haverkamp W, Breithardt G, Schmahl W, Peters C, Reinheckel T: Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci USA 2002:99:6234-6239.
32. Böhm M, Lippoldt A, Wienen W, Ganten D, Bader M: Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 1996; 164: 217-221.
33. Gohlke P, Linz W, Schölkens BA, Wiemer G, Unger T: Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996:28:397-402.
34. Inada Y, Wada T, Ojima M, Sanada T, Shibouta Y, Kanagawa R, Ishimura Y, Fujisawa Y, Nishikawa K: Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19:1079-1099.
35. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moyé L, Braunwald E: ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-1581.
36. Kim S, Yoshiyama M, Izumi T, Kawano H, Kimoto M, Zhan W, Iwao H: Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001; 103:148-154.
37. Nakamura Y, Yoshiyama M, Omura T, Yoshida K, Izumi Y, Takeuchi K, Kim S, Iwao H, Yoshikawa J: Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction. Cardiovasc Res 2003;57:48-54.
38. Brooks WW, Bing OH, Robinson KG, Slawsky MT, Chaletsky DM, Conrad CH: Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997;96:4002-4010.
39. Brilla CG, Janicki JS, Weber KT: Cardiore-parative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991;83:1771-1779.
40. Greive KA, Nikolic-Paterson DJ, Guimarães MA, Nikolovski J, Pratt LM, Mu W, Atkins RC, Comper WD: Glomerular permselectivity factors are not responsible for the increase in fractional clearance of albumin in rat glomerulonephritis. Am J Pathol 2001; 159: 1159-1170.
41. Di Giorgio J: Creatinine and creatine; in Henry RJ, Canon DC, Winkelman JW (eds): Clinical Chemistry: Principles and Techniques. Baltimore, Harper & Row, 1974, pp 541-548.
42. Kominami E, Tsukahara T, Bando Y, Katunuma N: Distribution of cathepsins B and H in rat tissues and peripheral blood cells. J Biochem 1985;98:87-93.
43. Bando Y, Kominami E, Katunuma N: Purification and tissue distribution of rat cathepsin L. J Biochem 1986; 100:35-42.
44. Gilbert RE, Wilkinson-Berka JL, Johnson DW, Cox A, Soulis T, Wu LL, Kelly DJ, Jerums G, Pollock CA, Cooper ME: Renal expression of transforming growth factor-β inducible gene-h3 (β ig-h3) in normal and diabetic rats. Kidney Int 1998; 54:1052-1062.
45. 1 heterozygous mice. J Mol Cell Cardiol 2000; 32: 187-195.
46. Osicka TM, Yu Y, Panagiotopoulos S, Clavant SP, Kiriazis Z, Pike RN, Pratt LM, Russo LM, Kemp BE, Comper WD, Jerums G: Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 2000;49:87-93.
47. Osicka TM, Forbes JM, Thallas V, Brammar GC, Jerums G, Comper WD: Ramipril prevents microtubular changes in proximal tubules from streptozotocin diabetic rats. Nephrology (Carlton) 2003;8:205-211.
48. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, Raffaele J, Tsalamandris C: Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and mi-croalbuminuria. Am J Kidney Dis 2001;37: 890-899.
49. Chan JC, Critchley JA, Tomlinson B, Chan TY, Cockram CS: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997; 17:72-80.
50. 2 attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 2001; 170:647-651.
51. Dahly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, Roman RJ: Antihypertensive effects of chronic anti-TGF-β antibody therapy in Dahl S rats. Am J Physiol 2002;283: R757-R767.
52. 1 suppress intimal hyperplasia in a rat model. J Clin Invest 1994;93:1172-1178.
53. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522-530.
54. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015-8020.
55. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992;360:361-364.
56. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996;2:418-423.
57. 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 1996; 118: 213-221.
58. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T: Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106:130-135.
59. Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, Krum H, Wilkinson-Berka J, Gilbert RE: Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-β. Cardiovasc Res 2005;65:694-701.
60. Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, Liapis H, Klahr S, Hruska KA: Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic ne-phropathy. Kidney Int 2003;63:2037-2049.
61. Kim HW, Kim BC, Song CY, Kim JH, Hong HK, Lee HS: Heterozygous mice for TGF-βIIR gene are resistant to the progression of streptozotocin-induced diabetic nephropathy. Kidney Int 2004;66:1859-1865.